NIB net profit beats expectations

Published 20-AUG-2018 11:16 A.M.


1 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Name: NIB Holdings Ltd (ASX:NHF)

Market Capitalisation: $3 billion

Opening Share Price: $6.59

NIB Holdings (ASX:NHF) has reported a full year underlying operating profit of $184.81 million for the 12 months to 30 June 2018, an increase of more than 20% on the previous financial year.

Net profit after tax (NPAT) grew 11.1% to $133.5 million and statutory earnings per share by 8.0% to 29.4 cents per share.

The net profit of $133.5 million was ahead of consensus forecasts of $128 million and the full year dividend of 20 cents per share was broadly in line with analyst’s expectations.

Management said that the company was experiencing ongoing solid growth across its businesses.

In particular, management pointed to its Australian resident’s health insurance business which, on the back of organic growth and the October 2017 acquisition of GU Health, generated growth of 12.1% premium revenue to $1.9 billion.

On the score of organic growth, the group outperformed the industry average and margins in the Australian resident business were higher than the company had targeted due to lower claims inflation relative to historic levels.

NIB is targeting operating profit of at least $159 million in 2019, implying year-on-year growth of nearly 20%.

Note that any decision with regards to adding this stock to your portfolio should be taken with caution and professional financial advice sought.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.


Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free